Germline intergenic duplications at Xq26.1 underlie

Bazex-Dupré-Christol syndrome, an inherited basal cell carcinoma

susceptibility condition

Authors: Yanshan Liu^{1,†}, Siddharth Banka^{2,3,†,*}, Yingzhi Huang^{1,†}, Jonathan

Hardman-Smart^{4,5}, Derek Pye⁴, Antonio Torrelo⁶, Glenda M. Beaman^{2,3},

Marcelo G. Kazanietz⁷, Martin J Baker⁷, Carlo Ferrazzano⁸, Chenfu Shi⁸,

Gisela Orozco⁸, Stephen Eyre⁸, Michel van Geel^{9,10}, Anette Bygum^{11,12}, Judith

Fischer¹³, Zosia Miedzybrodzka^{14,15}, Faris Abuzahra¹⁶, Albert Rübben¹⁷, Sara

Cuvertino², Jamie M. Ellingford^{2,3}, Miriam J. Smith^{2,3}, D. Gareth Evans^{2,3},

Lizelotte J.M.T Weppner-Parren¹⁸, Maurice A.M. van Steensel^{19,20}, Iskander H.

Chaudhary²¹, D. Chas Mangham²², John T. Lear^{4,23}, Ralf Paus^{4,24,25}, Jorge

Frank ^{26,§}, William G. Newman^{2,3,§,*}, Xue Zhang^{1,§,*}

Affiliations:

¹McKusick-Zhang Center for Genetic Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union

Medical College, Beijing 100005, China.

²Division of Evolution, Infection and Genomics, Faculty of Biology,

Medicine and Human Sciences, University of Manchester, Manchester,

M13 9PL, United Kingdom.

³Manchester Centre for Genomic Medicine, Manchester University NHS

Foundation Trust, Manchester, M13 9WL, United Kingdom.

⁴The Centre for Dermatology Research, University of Manchester, MAHSC, and National Institutes of Health Biomedical Research Center, Manchester, M13 9PL, United Kingdom.

⁵St John's Institute of Dermatology, Kings College London, London, WC2R 2LS, United Kingdom.

⁶Department of Dermatology, Hospital Infantil Universitario Niño Jesús,

28009 Madrid, Spain.

⁷Department of Systems Pharmacology and Translational Therapeutics,

Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

19104, United States.

⁸Centre for Genetics and Genomics Versus Arthritis Division of

Musculoskeletal and Dermatological Sciences, School of Biological

Sciences, Faculty of Biology, Medicine and Health, University of

Manchester, Manchester, M13 9PL, United Kingdom.

⁹Department of Dermatology, University Hospital Maastricht, 6229

Maastricht, The Netherlands.

¹⁰GROW School for Oncology and Developmental Biology, Maastricht

University Medical Center +, 6229 Maastricht, The Netherlands.

¹¹Department of Clinical Genetics, Odense University Hospital, 5230

Odense, Denmark

¹²Hospital Clinical Institute, University of Southern Denmark, 5230 Odense, Denmark.

¹³Institute of Human Genetics, Medical Center, University of Freiburg,

79106 Freiburg, Germany.

¹⁴School of Medicine, Medical Sciences, Nutrition and Dentistry, University

of Aberdeen, Aberdeen AB25 2ZD, United Kingdom.

¹⁵Medical Genetics Department, NHS Grampian, Foresterhill, Aberdeen,

AB25 2ZD, United Kingdom.

¹⁶Department of Dermatology, Zaandam Medical Center, 1502 Zaandam,

The Netherlands.

¹⁷Department of Dermatology and Allergology, University Hospital of

RWTH Aachen, 52062 Aachen, Germany.

¹⁸Department of Dermatology, Jeroen Bosch Hospital, 5223

's-Hertogenbosch, the Netherlands.

¹⁹Skin Research Institute of Singapore, Agency for Science, Technology

and Research (A*STAR), Singapore 138543, Singapore.

²⁰Lee Kong Chian School of Medicine, Nanyang Technological University

(NTU), Singapore 636921, Singapore.

²¹Department of Pathology, Royal Liverpool University Hospital, Liverpool,

L7 8XP, UK

²²Adult Histopathology, Laboratory Medicine, Manchester University NHS Foundation Trust, Health Innovation Manchester, Manchester, M13 9WL, United Kingdom. ²³Department of Dermatology, Salford Royal NHS Foundation Trust,

Manchester, M6 8AD, United Kingdom.

²⁴Dr Phillip Frost Department of Dermatology & Cutaneous Surgery,

University of Miami Miller School of Medicine, Miami, FL 33125, United

States.

²⁵Monasterium Laboratory, Nano-Bioanalytik Zentrum, D - 48149 Münster,

Germany

²⁶Dept. of Dermatology, Venereology and Allergology, University Medical

Center Göttingen, 37075 Göttingen, Germany

^{†, §} Equal contribution

*Correspondence to

Xue Zhang, McKusick-Zhang Center for Genetic Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, China. Phone: (+86)-10-65105154. E-mail: <u>xuezhang@pumc.edu.cn</u>;

William G. Newman, Division of Evolution, Infection and Genomics, Faculty of Biology, Medicine and Human Sciences, University of Manchester, Manchester, M13 9PL, United Kingdom. E-mail: william.newman@manchester.ac.uk

Siddharth Banka, Division of Evolution, Infection and Genomics, Faculty of Biology, Medicine and Human Sciences, University of Manchester,

4

Manchester, M13 9PL, United Kingdom. E-mail:

Siddharth.Banka@manchester.ac.uk

Abstract

Background: Bazex-Dupré-Christol syndrome (BDCS; MIM301845) is a rare X-linked dominant genodermatosis characterized by follicular atrophoderma, congenital hypotrichosis and multiple basal cell carcinomas (BCCs). Previous studies have linked BDCS to an 11.4 Mb interval on chromosome Xq25-27.1. However, the genetic mechanism of BDCS remains an open question.

Methods: To investigate the genetic etiology of BDCS, we ascertained eight families with individuals affected with BDCS (F1-F8). Whole exome (F1 and F2) and genome sequencing (F3) were performed to identify putative disease-causing variants within the linkage region. Array-comparative genomic hybridization and quantitative PCR were used to explore copy number variations (CNV) in BDCS families, followed by long-range gap-PCR and Sanger sequencing to amplify duplication junction and define the precise head-tail junctions, respectively. Immunofluorescence was performed in hair follicles, BCCs and trichoepitheliomas from BDCS patients and sporadic BCCs to detect the expression of corresponding genes. The *ACTRT1* variant (p.Met183Asnfs*17), previously proposed to cause BDCS, was evaluated with allele frequency calculator.

Results: In eight BDCS families, we identified overlapping 18-135kb duplications (six inherited and two *de novo*) at Xq26.1, flanked by *ARHGAP36* and *IGSF1*. We detected ARHGAP36 expression near the control hair follicular stem cells compartment, and found increased ARHGAP36 levels in hair follicles in telogen, BCCs and trichoepitheliomas from patients with BDCS. ARHGAP36 was also detected in sporadic BCCs from individuals without BDCS. Our modelling showed the predicted *ACTRT1* variants maximum tolerated

6

minor allele frequency in control populations to be orders of magnitude higher than expected for a high-penetrant ultra-rare disorder, suggesting loss-of-function of *ACTRT1* is unlikely to cause BDCS.

Conclusions: Our data support the pathogenicity of intergenic duplications at Xq26.1,

most likely leading to dysregulation of ARHGAP36, establish BDCS as a genomic disorder,

and provide a potential therapeutic target for both inherited and sporadic BCCs.

Keywords: Bazex-Dupré-Christol syndrome, basal cell carcinomas, copy

number variation, ARHGAP36

1 Background

2 Bazex-Dupré-Christol syndrome (BDCS, also called Bazex syndrome or follicular 3 atrophoderma and basal cell carcinomas; MIM 301845) is a rare X-linked disorder 4 characterized by congenital hypotrichosis, follicular atrophoderma (seen as "ice pick" 5 marks, usually on the dorsum of hands and feet) and susceptibility to develop basal cell 6 nevi and basal cell carcinomas (BCCs). The nevi and BCCs generally occur on 7 sun-exposed areas, including the head, neck and face from the second decade of life [1]. 8 Other features reported in some individuals with BDCS include persistent milia, 9 hyperpigmented macules, hypohidrosis, and trichoepitheliomas (benign tumors arising 10 from basal cells in the hair follicles, which rarely transform to BCCs) [2-9]. 11 Clinically, BDCS overlaps with basal cell nevus syndrome (Gorlin syndrome: MIM 12 109400), which predisposes to multiple BCCs and is caused by heterozygous germline 13 variants in PTCH1 [10, 11] or SUFU [12]. Both genes encode members of the hedgehog 14 signaling pathway, and variants in them result in dysregulated overexpression of Gli 15 transcription factors. BCC is the most common skin cancer [13], with somatic mutations 16 in genes encoding key components of Hedgehog-Patched-Gli signalling often present in 17 sporadic BCCs [14]. BCCs arise from hair follicle stem cells and/or other epithelial stem cells reprogrammed to a follicular differentiation [15, 16]. Of note, X-linked inheritance 18 19 pattern is unusual for a cancer predisposition syndrome. The 'two-hit model' for familial 20 cancers caused by loss of heterozygosity of the remaining functional allele in an 21 individual with a germline loss-of-function variant is unlikely to occur for an X-linked 22 tumor suppressor gene. Hence, we hypothesized that BDCS is caused by genetic

8

- 1 variants resulting in altered Hedgehog-Patched signaling or -Gli activity in follicular stem
- 2 cells via a mechanism that does not result in direct loss of function.
- 3 Methods

4 **Patient ascertainment**

- 5 The procedures followed were in accordance with the ethical standards of the
- 6 responsible committee on human experimentation (institutional and national), and written
- 7 informed consents to take part in the present study, as well as to have the results of this
- 8 work published were obtained from the participants. We identified patients and families
- 9 diagnosed with BDCS based on clinical history and examination.

10 Sanger sequencing

- 11 A single primer pair (ACTRT1-F: TAGGTATGATTTGCTTTCCTTGGC, ACTRT1-R-R:
- 12 CAACCTAAAGATTCATGACATGACTC) was designed to amplify the full length of
- 13 ACTRT1, which encompassed the single coding exon and its 5 'and 3 'untranslated
- regions (UTR). At least one affected individual from each family underwent Sanger

15 sequencing.

- 16 All coding exons of *ARHGAP36* (exons 2-12) were amplified in the panel of lymphocyte
- 17 DNA samples from individuals with clinical diagnoses of Gorlin syndrome without causal
- 18 variants in *PTCH1* or *SUFU* and underwent Sanger sequencing on an ABI3730xI DNA
- 19 Analyser (Life Technologies, Paisley, UK).

20 Exome and Genome sequencing

- 21 Whole exome sequencing was performed by using SureSelect kits (Human All Exon
- 50Mb for Families 1 and 2 and Human All Exon v.5 for Family 3) (both Agilent, Santa

1	Clara, CA, USA) were used for whole exome sequencing. Paired-end sequencing
2	(~100bp) was performed on Illumina HiSeq2000 (Family 1 and 2) or HiSeq2500
3	platforms (Family 3). For the first two families, a minimum of 4.3 Gb of high-quality
4	mappable data was generated, yielding a mean depth of coverage of 40-fold and 84% of
5	target bases sequenced at 10x coverage. A minimum of 4.5 Gb of sequence was
6	generated, yielding a mean depth of coverage of 80-fold and 95% of target bases
7	sequenced at 20x coverage. The sequence data were mapped to the human reference
8	genome (hg19) using Burrows Wheeler Aligner [17]. Variant calling was performed using
9	the GenomeAnalysisToolKit-v2.4.7. (GATK) software [18]. Genome sequence data was
10	generated by Complete Genomics (Mountain View, California, USA) as described
11	previously [19]. Bioinformatics (alignment to the hg19 reference genome, local de novo
12	assembly and variant calling) was performed using version 2.5 of the Complete
13	Genomics pipeline [20].
14	Array-comparative genomic hybridisation (a-CGH)
15	A-CGH was performed using Affymetrix SNP6.0 microarray as described previously [21].
16	Real-time quantitative PCR (qPCR)
17	To validate the genomic duplications detected by aCGH and determine the boundaries
18	of duplications in the three families and other families, qPCR was performed as
19	previously described [22]. For families 1, 2 and 7, the primers for qPCR were designed

20 according to aCGH results. For the other families, primer pair XQM located in the middle

- of the shared duplicated region (chrX:130348186-130348315) was designed. The
- 22 quantification of the target regions was normalized to an assay from chromosome 21.
- 23 The relative copy number (RCN) was determined with the comparative $\Delta\Delta$ CT method,
- 24 using DNA from a normal male as the calibrator. All assays were repeated three times. A

- 1 ~2-fold RCN indicated duplication in samples from males and ~3-fold RCN for samples
- 2 from females. Primers used for each family were listed in Supp Table 3.

3 Haplotype analysis

- 4 Four common single nucleotide polymorphisms (SNPs) (rs62603806, rs4240127,
- 5 rs5932866, rs12559533) within the duplicated region were amplified with primer pair
- 6 (SNP-F: GCACAGATGATTATGTCTGTTCC, SNP-R:
- 7 CTGTCCCTACTTAGTAAATCGAG) and Sanger sequenced to generate haplotypes in
- 8 the male patients of F1, F3, and F8.

9 Long-range Gap-PCR

- 10 A series of qPCR primers was designed to walk through to refine the duplication
- boundaries. Once the boundaries were estimated by qPCR, the forward primer from the
- 12 centromeric side of the duplication region that was nearest to the determined boundaries,
- 13 as well as the reverse primer from the telomeric side were chosen to perform long-range
- 14 gap-PCR in order to amplify the duplication junctions. F3, F5 and F8 used the same
- 15 primers pair as F1. Sanger sequencing was conducted to define the precise breakpoints.
- 16 Primers used for each family were listed in Supp Table 3.

17 **Population screening**

- 18 Primer pair XQM, as described above, was used to determine the frequency of
- 19 duplications at the disease associated locus by qPCR. The criteria defining duplication
- 20 was the same as above.

21 Immunohistochemistry

22 Immunohistochemistry was performed on 7um frozen sections by fixation in chilled

23 paraformaldehyde (4% v/v) for 10 minutes. After washing with phosphate buffered saline

1	(PBS), sections were permeabilised with PBS containing 0.1% Triton X100 for ten
2	minutes. Primary antibodies were incubated over night at 4°C at a concentration of 1:200
3	(ARHGAP36, HPA002064, Sigma, Dorset, UK), 1:20 (IGSH, HPA035582, Sigma) or
4	1:100 (ACTRT1, HPA003119, Sigma). For dual stains cytokeratin 15 (Abcam, ab80522,
5	Cambridge, UK), at a concentration of 1:500 was added and incubated overnight.
6	Antibodies were detected by incubating with an Alexafluor goat anti mouse/rabbit
7	secondary (Sigma) antibody at a concentration of 1:200 for 45 minutes. Sections were
8	counterstained with DAPI.
9	For tumor tissue, paraffin sections were de-waxed using xylene and rehydrated using
10	decreasing concentrations of ethanol (100%-50%). Antigen retrieval was performed by
11	boiling in 10mM citrate buffer (pH 6) for 20 minutes. Following this the protocol as above
12	was followed with P63 (Abcam-ab735) at a concentration of 1:100.
13	Allele frequency modelling
13 14	Allele frequency modelling Allele frequency modelling of ACTRT1 was performed using the allele frequency
14	Allele frequency modelling of ACTRT1 was performed using the allele frequency
14 15	Allele frequency modelling of <i>ACTRT1</i> was performed using the allele frequency calculator from http://cardiodb.org/allelefrequencyapp [23].The maximum tolerated
14 15 16	Allele frequency modelling of <i>ACTRT1</i> was performed using the allele frequency calculator from http://cardiodb.org/allelefrequencyapp [23].The maximum tolerated reference allele count (0.95 CI) for the ACTRT1 NM_138289.3:c.547dup
14 15 16 17	Allele frequency modelling of <i>ACTRT1</i> was performed using the allele frequency calculator from http://cardiodb.org/allelefrequencyapp [23].The maximum tolerated reference allele count (0.95 CI) for the ACTRT1 NM_138289.3:c.547dup (p.(Met183Asnfs*17)) variant was calculated in 204,684 in alleles
14 15 16 17 18	Allele frequency modelling of <i>ACTRT1</i> was performed using the allele frequency calculator from http://cardiodb.org/allelefrequencyapp [23].The maximum tolerated reference allele count (0.95 Cl) for the ACTRT1 NM_138289.3:c.547dup (p.(Met183Asnfs*17)) variant was calculated in 204,684 in alleles (https://gnomad.broadinstitute.org/variant/X-127185638-A-AT?dataset=gnomad_r2_1).
14 15 16 17 18 19	Allele frequency modelling of <i>ACTRT1</i> was performed using the allele frequency calculator from http://cardiodb.org/allelefrequencyapp [23].The maximum tolerated reference allele count (0.95 CI) for the ACTRT1 NM_138289.3:c.547dup (p.(Met183Asnfs*17)) variant was calculated in 204,684 in alleles (https://gnomad.broadinstitute.org/variant/X-127185638-A-AT?dataset=gnomad_r2_1). The adjustable parameters were – estimated population prevalence of BDCS (1 in106)
14 15 16 17 18 19 20	Allele frequency modelling of <i>ACTRT1</i> was performed using the allele frequency calculator from http://cardiodb.org/allelefrequencyapp [23].The maximum tolerated reference allele count (0.95 Cl) for the ACTRT1 NM_138289.3:c.547dup (p.(Met183Asnfs*17)) variant was calculated in 204,684 in alleles (https://gnomad.broadinstitute.org/variant/X-127185638-A-AT?dataset=gnomad_r2_1). The adjustable parameters were – estimated population prevalence of BDCS (1 in106) (Orpha.net); allelic heterogeneity of 33% (BDCS in 2 out of 6 families in Bal et al was
14 15 16 17 18 19 20 21	Allele frequency modelling of <i>ACTRT1</i> was performed using the allele frequency calculator from http://cardiodb.org/allelefrequencyapp [23].The maximum tolerated reference allele count (0.95 CI) for the ACTRT1 NM_138289.3:c.547dup (p.(Met183Asnfs*17)) variant was calculated in 204,684 in alleles (https://gnomad.broadinstitute.org/variant/X-127185638-A-AT?dataset=gnomad_r2_1). The adjustable parameters were – estimated population prevalence of BDCS (1 in106) (Orpha.net); allelic heterogeneity of 33% (BDCS in 2 out of 6 families in Bal et al was attributed to this variant); and penetrance of 100% (based on description of families in
14 15 16 17 18 19 20 21 22	Allele frequency modelling of <i>ACTRT1</i> was performed using the allele frequency calculator from http://cardiodb.org/allelefrequencyapp [23].The maximum tolerated reference allele count (0.95 Cl) for the ACTRT1 NM_138289.3:c.547dup (p.(Met183Asnfs*17)) variant was calculated in 204,684 in alleles (https://gnomad.broadinstitute.org/variant/X-127185638-A-AT?dataset=gnomad_r2_1). The adjustable parameters were – estimated population prevalence of BDCS (1 in106) (Orpha.net); allelic heterogeneity of 33% (BDCS in 2 out of 6 families in Bal et al was attributed to this variant); and penetrance of 100% (based on description of families in the literature. Next, to account for potential inaccuracies in previous estimates, we

1 Results

2 BDCS is caused by small tandem intergenic duplications at chromosome Xq26.1

3 Previous mapping has linked BDCS to an 11.4 Mb interval on chromosome Xq25-27.1 4 [24, 25]. To further investigate the genetic etiology of BDCS, we ascertained eight 5 families (F1-8) with individuals affected with BDCS (Fig. 1), including five previously 6 published families (F1 [25], F4 [26], F5 [27], F7 [3], and F8 [28]). Whole exome (F1 and 7 F2) or genome (F3) sequencing did not identify putative disease-causing variants within 8 the Xq26.1 locus previously linked to BDCS [25]. Array-comparative genomic 9 hybridization in at least one affected individual from F1, F2, F3, and F7 revealed small 10 intergenic Xq26.1 gains of varying sizes (Fig. 2A) [25]. Further, qPCR assays in affected 11 individuals from the other four families (F4, F5, F6, and F8) were consistent with gains at this locus and confirmed that the gains segregated with BDCS in the multiplex families or 12 13 were *de novo* in the two simplex cases (Fig. 2B). Long-range gap-PCR to amplify the 14 duplication junctions followed by Sanger sequencing defined the head-tail junctions for 15 F2, F4, F6 and F7 and confirmed these gains as tandem duplications (Fig. 2C). The 16 duplications in F1, F3, F5, and F8 could not be differentiated further, likely due to 17 homologous L1 elements (Fig. 2D). In the three multiplex families (F1, F3 and F8) with seemingly identically sized duplications, SNP haplotype mapping proved their likely 18 19 independent origin (Fig. 2E). No gains were identified by qPCR in 215 unrelated 20 European controls (139 females and 76 males). The largest gain was detected in F2 21 (135kb) and the 18kb gain in F6 defined the smallest shared overlapping region (hg19, 22 chrX:130,341,750-130,360,310) (Fig. 2D).

No similar sized exclusively intergenic gains overlapping with the shared duplicated
 region defined by the eight families were detected in control populations (Fig. S1). One

1 entirely intergenic gain (nsv517789; chrX:130,234,700-130,340,623) of ~100kb, in an 2 individual with no known phenotype was noted, but it did not overlap the shared 3 duplicated region as defined by our study (Fig. S1) [29]. Another gain of >380kb 4 (nsv528179; chrX:130,300,617-130,680,930) overlapping the shared BDCS duplicated 5 region, in an individual with no known phenotype was noted, but it extended ~295kb 6 beyond the most telomeric boundary of the BDCS associated duplications and 7 encompasses IGSF1 (Fig. S1). Other larger chromosome X duplications encompassing 8 the region have also been reported in individuals without BDCS [29].

9 The Xq26.1 duplications in BDCS likely dysregulate ARHGAP36

10 None of the BDCS duplications encompass protein-coding genes, suggesting 11 dysregulation of flanking genes as the likely disease-associated mechanism (Fig. 2D). 12 BDCS is considered to be a disorder of the hair follicle [5]. We, therefore, performed 13 immunofluorescence for the two flanking genes, ARHGAP36 and IGSF1 in control hair 14 follicles. In anagen, IGSF1 was present in the terminally differentiated inner root sheath 15 (IRS), but was absent from the actively proliferating hair matrix or bulge, the main 16 reservoir of hair follicle epithelial stem cells (Fig. S3a). In telogen, there was no evidence 17 of IGSF1 staining (data not shown). In contrast, ARHGAP36 was present in a small number of hair follicle cells in the outer root sheath (ORS) at the level of the stem cell 18 19 bulge, in both anagen (Fig. 3A) and telogen (Fig. 3C). Notably, it is at the end of telogen 20 that the stem cells located in the secondary hair germ and bulge regions are activated to 21 resume hair growth [30]. There was no obvious difference regarding ARHGAP36 positive 22 cell numbers in the ORS between hair follicles from healthy control and an individual with 23 BDCS (F5:II-1) in anagen (Fig. 3A and 3B). In contrast, in telogen hair follicle from F5:II-1, 24 there was a marked increase in the number of ARHGAP36 positive cells around the

epithelial stem cell compartment (Fig. 3D), comparing with healthy control in telogen
(Fig.3C) and the same patient in anagen (Fig. 3B). Moreover, immunofluorescence in
histologically confirmed p63 positive BCC [31] from F4:III-4 showed strong staining for
ARHGAP36 in a proportion of cells (Fig. 4A-B). Notably, the BCCs did not
immunofluoresce for IGSF1 (Fig. S4a). We also detected striking ARHGAP36 staining of
a trichoepithelioma from the same individual (Fig. 4C).

Next, to explore if ARHGAP36 could be relevant to sporadic BCCs, we determined the presence of ARHGAP36 in superficial (n=10), nodular (n=10), and infiltrative (n=10) sporadic BCCs. Similar to the BCCs in BDCS, ARHGAP36 was present in a small proportion of cells from all examined tumors (Fig. 4D-F), but was absent from all surrounding tissue.

12 ACTRT1 loss-of-function variants are unlikely to cause BDCS

Knudson's two-hit hypothesis explains the mechanism of most inherited cancer 13 14 syndromes, in which tumors occur following somatic loss of the only functional allele in 15 an individual with a germline loss-of-function variant in a tumor suppressor gene [32]. 16 Presence of a single X-chromosome in males and X-inactivation in females, make 17 X-linked inherited cancer predisposition syndromes due to tumor gene suppression highly unlikely. Previously, Bal et al reported loss-of-function ACTRT1 variants in BDCS 18 19 [28]. They identified a frameshift ACTRT1 NM 138289.3: c.547dup (p.Met183Asnfs*17) 20 variant (rs771087307), in two families with BDCS [28]. Variants in conserved non-coding 21 elements flanking ACTRT1 were also proposed as pathogenic. Our modelling revealed that the predicted maximum tolerated minor allele frequency (MAF) for the 22 p.Met183Asnfs*17 variant in population control data to be ~10⁴ times higher than 23

1 expected and could be reconciled only if the previous prevalence and penetrance 2 estimates were inaccurate by several orders of magnitude (Fig. 5). Furthermore, other 3 putative loss-of-function variants in the single exon of ACTRT1 have been reported in 4 both males and females without BDCS (Tables S1-2). Sanger sequencing in at least one 5 affected individual from F1-F7 did not identify any rare coding variants in ACTRT1. As expected, the p. Met183Asnfs*17 variant was present in the affected individuals (II-1 and 6 7 III-1) in F8, as reported in the original association paper [28]. Importantly, 8 immunofluorescent staining showed that ACTRT1 was absent from both the 9 disease-relevant regions of the hair follicles and tumors from individuals with BDCS (Fig. 10 S3b and S4b). These combined data provide evidence that ACTRT1 loss-of-function 11 variants are unlikely to cause BDCS.

12 **DISCUSSION**

13 We show that BDCS is caused by small intergenic tandem duplications at Xg26.1 that 14 encompass а minimum shared overlapping region of ~18Kb 15 (chrX:130,341,750-130,360,310) (Fig. 2). Identification of a BDCS duplication at this locus in a family previously reported to have a causal ACTRT1 variant is indicative of the 16 17 likely benign nature of ACTRT1 variants in individuals with BDCS [28, 33]. Importantly, 18 our data suggests that larger Xq26.1 duplications *encompassing* the flanking genes in 19 addition to the minimum common shared region may not result in BDCS. Also, smaller 20 'non-coding' duplications at Xg26.1 that do not overlap the shared minimum overlapping 21 region may not cause BDCS. These observations reflect the complexity of the genetic 22 diagnosis of BDCS and assigning pathogenicity to Xq26.1 duplications in diagnostic labs 23 will require careful consideration of the size and location of the copy number gains at this

position. Future studies will be needed to validate our findings and to refine the minimum
 common overlapping region for BDCS duplications.

3 To the best of our knowledge, BDCS is the first example of an inherited cancer 4 predisposition disease caused by germline CNVs that do not encompass any protein 5 coding genes. To explore the effects of the intergenic BDCS duplications, we first turned 6 our attention to the two flanking genes, as our preliminary Hi-C assay on dermal 7 fibroblasts from health control and BDCS patients showed that the of BDCS duplications 8 did not disrupt the topologically associated domain (TAD), which contained IGSF1 and 9 ARHGAP36 (Fig. S5). IGSF1, the flanking telomeric gene, encodes member 1 of the 10 immunoglobulin superfamily and loss-of-function variants in this gene cause an X-linked 11 recessive syndrome of central hypothyroidism and testicular enlargement (MIM 300888) 12 [34]. There is no known role of IGSF1 in Hedgehog-Patched-Gli pathway. ARHGAP36, 13 the flanking centromeric gene, encodes a Smoothened (Smo)-independent positive 14 regulator of the sonic hedgehog (shh) pathway and its expression is upregulated in 15 medulloblastomas, a Hedgehog-Patched-Gli pathway-related tumor [35, 36]. Variants in 16 ARHGAP36 have not been associated with any inherited disorder. Hence, the known 17 biological role makes ARHGAP36 an excellent candidate for BDCS pathology. In this 18 context, our finding of ARHGAP36 expression is increased in telogen phase in follicles, 19 in BCCs and trichoepithelioma from BDCS patients (Fig. 3D, 4B and 4C) makes it highly 20 likely that ARHGAP36 dysregulation is the likely disease mechanism.

Interestingly, our results suggest that ARHGAP36 is also relevant to sporadic BCC
pathology (Fig. 4D-F). Of note, ARHGAP36 did not co-localize with p63 (Fig. 4C-F) and
the higher levels of ARHGAP36 in trichoepithelioma than in the BDCS-associated and

17

1	sporadic BCCs suggests that dysregulation of ARHGAP36 may be an early step in the					
2	pathogenesis to BCC. ARHGAP36, therefore, could be an attractive therapeutic target					
3	for inhibition in individuals with both inherited and, the vastly more common,					
4	non-inherited forms of BCC.					
5	ARHGAP36 is a member of the Rho GAP family of regulatory proteins, which deactivate					
6	Rho proteins. Rac1 (a RhoGTPase) is essential for hair follicle stem cell function [37, 38].					
7	With pulldown assays, we demonstrated interaction between ARHGAP36 and RAC1 (Fig.					
8	S6). This preliminary finding potentially uncovers a previously unknown role of					
9	ARHGAP36 and may explain the non-cancerous phenotypes of BDCS, namely					
10	hypotrichosis. However, further confirmatory studies will be required to solve the mystery					
11	underlying ARHGAP36 dysregulation and BDCS phenotypes.					
12	Conclusions					
13	In summary, we have shown that small intergenic non-coding tandem duplications at					
14	Xq26.1 encompassing chrX:130,341,750-130,360,310 (hg19) cause BDCS. This is the					
15	first example of an inherited cancer predisposition disease caused by germline					
16	non-coding CNVs. We propose that the duplications result in the dysregulation of					
17	ARHGAP36 that underlies BDCS pathology. Our findings reconcile the molecular					
18	mechanism of BDCS, a tumor-predisposition syndrome, with its X-linked inheritance					
19	pattern. We also suggest that ARHGAP36 is relevant to sporadic BCCs and a potential					
20	therapeutic target.					

21 **Funding:**

XZ is supported by the National Natural Science Foundation of China (NSFC)
[grant number 81788101], the CAMS Innovation Fund for Medical Sciences

1	(CIFMS) [grant numbers 2021-I2M-1-018 and 2016-I2M-1-002] and National Key
2	Research and Development Program of China [grant number 2016YFC0905100].
3	MJS, DGE, RP and WGN are supported by the Manchester NIHR Biomedical
4	Research Centre (IS-BRC-1215-20007). ZM supported by NHS Grampian
5	Biorepository (NHS Scotland). JME is funded by a postdoctoral research
6	fellowship from the Health Education England Genomics Education Programme
7	(HEE GEP).
8	Authors' contributions:
9	XZ, JF and WGN conceived the project. XZ designed and coordinated the genetics study.
10	WGN and SB designed and directed the histopathology study. YL, YH, MGK, MJB, GO,
11	SE, JTL and RP conducted the experiments. YL, YH, JHS, DP, GMB, MGK, CF, CS, SC,
12	JME, MJS, IHC, SB, AT, MvG, AB, JF, ZM, FA, AR, DGE, LJMTW-P, MAMvS, DCM, JF
13	and WGN collected clinical data. SB, YL, YH, JF, WGN and XZ wrote the manuscript.
14	Availability of data and materials

- 15 WES, WGS and array-comparative genomic hybridization datasets have not been
- 16 deposited in a public repository due to privacy and ethical restrictions, but are available
- 17 from the corresponding authors on reasonable request.

18 Ethics approval and consent to participate

- 19 The procedures followed were in accordance with the ethical standards of the
- 20 responsible committee on human experimentation (institutional and national), and written
- 21 informed consents to take part in the present study, as well as to have the results of this
- 22 work published were obtained from the participants .
- 23 Competing interests

The authors declare no competing interests. 1

2 **References:**

- 3 1. Bazex AD, A.; Christol, B. Genodermatose complexe de type indetermine associant une
- 4 hypotrichose, un etat atrophodermique generalise et des degenerescences cutanees multiples. 5
- Bull Soc Franc Derm Syph. 1964;71
- 6 2. Plosila M, et al. The Bazex syndrome: follicular atrophoderma with multiple basal cell
- 7 carcinomas, hypotrichosis and hypohidrosis. Clin Exp Dermatol. Jan 1981;6(1):31-41.
- 8 doi:10.1111/j.1365-2230.1981.tb02265.x
- 9 3. Herges A, et al. [Bazex-Dupre-Christol syndrome. Follicular atrophoderma, multiple basal cell
- 10 carcinomas and hypotrichosis]. Hautarzt. Jun 1993;44(6):385-91. Das
- 11 Bazex-Dupre-Christol-Syndrom. Follikulare Atrophodermie, multiple Basaliome und
- 12 Hypotrichose.
- 13 4. Vabres P, de Prost Y. Bazex-Dupre-Christol syndrome: a possible diagnosis for basal cell
- 14 carcinomas, coarse sparse hair, and milia. Am J Med Genet. Mar 15 1993;45(6):786.
- 15 doi:10.1002/ajmg.1320450628
- 16 5. Goetevn M, et al. The Bazex-Dupre-Christol syndrome. Arch Dermatol. Mar
- 17 1994;130(3):337-42.
- 18 6. Yung A, Newton-Bishop JA. A case of Bazex-Dupre-Christol syndrome associated with
- 19 multiple genital trichoepitheliomas. Br J Dermatol. Sep 2005;153(3):682-4.
- 20 doi:10.1111/j.1365-2133.2005.06819.x
- 21 7. Barcelos AC, Nico MM. Bazex-Dupre-Christol syndrome in a 1-year-old boy and his mother.
- 22 Pediatr Dermatol. Jan-Feb 2008;25(1):112-3. doi:10.1111/j.1525-1470.2007.00596.x
- 23 8. Castori M, et al. Bazex-Dupre-Christol syndrome: an ectodermal dysplasia with skin
- 24 appendage neoplasms. Eur J Med Genet. Jul-Aug 2009;52(4):250-5.
- 25 doi:10.1016/j.ejmg.2008.12.003
- 26 9. Kallam AR, et al. Basal Cell Carcinoma Developing from Trichoepithelioma: Review of
- 27 Three Cases. J Clin Diagn Res. Mar 2016;10(3):PD17-9. doi:10.7860/JCDR/2016/15432.7464
- 28 10. Hahn H, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal
- cell carcinoma syndrome. Cell. Jun 14 1996;85(6):841-51. doi:10.1016/s0092-8674(00)81268-4 29
- 30 11. Johnson RL, et al. Human homolog of patched, a candidate gene for the basal cell nevus
- 31 syndrome. Science. Jun 14 1996;272(5268):1668-71. doi:10.1126/science.272.5268.1668
- 32 12. Smith MJ, et al. Germline mutations in SUFU cause Gorlin syndrome-associated childhood
- 33 medulloblastoma and redefine the risk associated with PTCH1 mutations. J Clin Oncol. Dec 20
- 34 2014;32(36):4155-61. doi:10.1200/JCO.2014.58.2569
- 13. Peris K, et al. Diagnosis and treatment of basal cell carcinoma: European consensus-based 35
- 36 interdisciplinary guidelines. Eur J Cancer. Sep 2019;118:10-34. doi:10.1016/j.ejca.2019.06.003
- 37 14. Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer. Oct
- 38 2008;8(10):743-54. doi:10.1038/nrc2503
- 39 15. Peterson SC, et al. Basal cell carcinoma preferentially arises from stem cells within hair
- 40 follicle and mechanosensory niches. Cell Stem Cell. Apr 2 2015;16(4):400-12.
- 41 doi:10.1016/j.stem.2015.02.006
- 42 16. Youssef KK, et al. Adult interfollicular tumour-initiating cells are reprogrammed into an
- 43 embryonic hair follicle progenitor-like fate during basal cell carcinoma initiation. Nat Cell Biol.
- 44 Dec 2012;14(12):1282-94. doi:10.1038/ncb2628

- 1 17. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform.
- 2 Bioinformatics. Jul 15 2009;25(14):1754-60. doi:10.1093/bioinformatics/btp324
- 3 18. McKenna A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing
- 4 next-generation DNA sequencing data. *Genome Res.* Sep 2010;20(9):1297-303.
- 5 doi:10.1101/gr.107524.110
- 6 19. Drmanac R, et al. Human genome sequencing using unchained base reads on self-assembling
- 7 DNA nanoarrays. Science. Jan 1 2010;327(5961):78-81. doi:10.1126/science.1181498
- 8 20. Carnevali P, et al. Computational techniques for human genome resequencing using mated
- 9 gapped reads. J Comput Biol. Mar 2012;19(3):279-92. doi:10.1089/cmb.2011.0201
- 10 21. Banka S, et al. Identification and characterization of an inborn error of metabolism caused by
- 11 dihydrofolate reductase deficiency. Am J Hum Genet. Feb 11 2011;88(2):216-25.
- 12 doi:10.1016/j.ajhg.2011.01.004
- 13 22. Sun M, et al. Triphalangeal thumb-polysyndactyly syndrome and syndactyly type IV are
- 14 caused by genomic duplications involving the long range, limb-specific SHH enhancer. *J Med*
- 15 Genet. Sep 2008;45(9):589-95. doi:10.1136/jmg.2008.057646
- 16 23. Whiffin N, et al. Using high-resolution variant frequencies to empower clinical genome
- 17 interpretation. Genet Med. Oct 2017;19(10):1151-1158. doi:10.1038/gim.2017.26
- 18 24. Vabres P, et al. The gene for Bazex-Dupre-Christol syndrome maps to chromosome Xq. J
- 19 Invest Dermatol. Jul 1995;105(1):87-91. doi:10.1111/1523-1747.ep12313359
- 20 25. Parren LJ, et al. Linkage refinement of Bazex-Dupre-Christol syndrome to an 11.4-Mb
- 21 interval on chromosome Xq25-27.1. Br J Dermatol. Jul 2011;165(1):201-3.
- 22 doi:10.1111/j.1365-2133.2011.10219.x
- 23 26. Kidd A, et al. A Scottish family with Bazex-Dupre-Christol syndrome: follicular
- 24 atrophoderma, congenital hypotrichosis, and basal cell carcinoma. J Med Genet. Jun
- 25 1996;33(6):493-7. doi:10.1136/jmg.33.6.493
- 26 27. Torrelo A, et al. What syndrome is this? Bazex-Dupre-Christol syndrome. *Pediatr Dermatol.*
- 27 May-Jun 2006;23(3):286-90. doi:10.1111/j.1525-1470.2006.00237.x
- 28. Bal E, et al. Mutations in ACTRT1 and its enhancer RNA elements lead to aberrant
- 29 activation of Hedgehog signaling in inherited and sporadic basal cell carcinomas. Nat Med. Oct
- 30 2017;23(10):1226-1233. doi:10.1038/nm.4368
- 31 29. MacDonald JR, et al. The Database of Genomic Variants: a curated collection of structural
- 32 variation in the human genome. *Nucleic Acids Res.* Jan 2014;42(Database issue):D986-92.
- 33 doi:10.1093/nar/gkt958
- 34 30. Schneider MR, et al. The hair follicle as a dynamic miniorgan. *Curr Biol*. Feb 10
- 35 2009;19(3):R132-42. doi:10.1016/j.cub.2008.12.005
- 36 31. Reis-Filho JS, et al. p63 expression in normal skin and usual cutaneous carcinomas. J Cutan
- 37 Pathol. Oct 2002;29(9):517-23. doi:10.1034/j.1600-0560.2002.290902.x
- 38 32. Knudson AG, Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci
- 39 USA. Apr 1971;68(4):820-3. doi:10.1073/pnas.68.4.820
- 40 33. Richards S, et al. Standards and guidelines for the interpretation of sequence variants: a joint
- 41 consensus recommendation of the American College of Medical Genetics and Genomics and the
- 42 Association for Molecular Pathology. *Genet Med.* May 2015;17(5):405-24.
- 43 doi:10.1038/gim.2015.30
- 44 34. Sun Y, et al. Loss-of-function mutations in IGSF1 cause an X-linked syndrome of central
- 45 hypothyroidism and testicular enlargement. *Nat Genet*. Dec 2012;44(12):1375-81.
- 46 doi:10.1038/ng.2453
- 47 35. Rack PG, et al. Arhgap36-dependent activation of Gli transcription factors. *Proc Natl Acad*
- 48 *Sci U S A*. Jul 29 2014;111(30):11061-6. doi:10.1073/pnas.1322362111

- 1 36. Beckmann PJ, et al. Sleeping Beauty Insertional Mutagenesis Reveals Important Genetic
- Drivers of Central Nervous System Embryonal Tumors. *Cancer Res.* Mar 1 2019;79(5):905-917.
 doi:10.1158/0008-5472.CAN-18-1261
- 4 37. Reijnders MRF, et al. RAC1 Missense Mutations in Developmental Disorders with Diverse
- 5 Phenotypes. Am J Hum Genet. Sep 7 2017;101(3):466-477. doi:10.1016/j.ajhg.2017.08.007
- 6 38. Behrendt K, et al. A function for Rac1 in the terminal differentiation and pigmentation of
- 7 hair. J Cell Sci. Feb 15 2012;125(Pt 4):896-905. doi:10.1242/jcs.091868
- 8
- 9 Figure Legends
- 10 **Fig. 1. Individuals with BDCS and pedigrees of families.** Pedigrees of all families
- 11 included in this study are shown. Standard symbols have been used to denote sex and
- 12 affected status. * indicates individuals from whom DNA samples were available for
- 13 analysis. At least one affected individual from each family underwent ACTRT1 Sanger
- 14 sequencing including its full coding region and the 5' and 3' untranslated regions. Figures
- 15 of BDCS patients from current study were available from the corresponding authors on
- 16 reasonable request.

17 Fig. 2. Small intergenic duplications of chromosome Xq26.1 in individuals with

18 **BDCS.** (A) Array comparative genomic hybridisation in four individuals with BDCS,

19 demonstrating intergenic copy number gains at the Xq26.1. The top four panels show the


- 20 corresponding copy number of F1:IV-3, F2:II-2, F3:III-3 and F7:II-1 between chrX:
- 21 130,150,000-130,450,000 (hg19), respectively. The bottom panel shows the flanking
- 22 RefSeq protein coding genes. (B) qPCR of an amplicon at the duplicated locus
- 23 demonstrating normal copy number (white bar) in the unaffected mothers of individuals
- 24 F5:II-1 and F6:II-1 consistent with de novo origin of the duplications in these affected
- 25 (black bar) individuals. In other families the presence of the duplications segregated with
- 26 the phenotype. *indicates different primer pair was used in F7 compared with other
- 27 families. (C) The specific breakpoints for the duplications defined in affected individuals


1	from families F2, F4, F6 and F7. (D) A cartoon of the duplications at Xq26.1-26.2 from
2	the eight families with BDCS, with individual F6:II-1 defining the boundaries of the critical
3	interval. (E) Long-range gap PCR in families' members of F1, F3, F5 and F8 had
4	seemingly identically sized duplications (top). Haplotype analysis with four common
5	single nucleotide polymorphisms (SNPs) (rs62603806, rs4240127, rs5932866,
6	rs12559533) within the duplicated region demonstrates independent origins of F1, F3
7	and F8 (down).
8	Fig. 3. Immunofluorescence of hair follicles in anagen and telogen from normal
9	healthy skin and an individual (F5:II-1) with BDCS for ARHGAP36. A small number
10	of cells in the stem cell bulge region stain positively (green) for ARHGAP36 in the hair
11	follicle from normal healthy skin (A) and the skin from F5:II-1 (B). (C) A normal hair
12	follicle in telogen stained for ARHGAP36 (green) demonstrating a small number of
13	positively stained cells in the outer root sheath adjacent to K15 positive bulge stem cells
14	(red). (D) A hair follicle in telogen from F5:II-1 showing an increased number of positively
15	stained cells. Red stain for keratin 15. (DP = dermal papilla; ORS = outer root sheath; HS
16	= hair shaft). Scale bar 50µm.
17	Fig. 4. Immunofluorescence of ARHGAP36 in BDCS patient and sporadic BCCs.
18	(A-C) Pathological study of tumors. Haematoxylin and eosin staining (A) and
19	immunofluorescence (B) in a BCC from an individual with BDCS (F4:III-4) demonstrating
20	staining (green) for ARHGAP36 in the tumor but not in the surrounding tissue. Strong
21	staining of a trichoepithelioma (C) for ARHGAP36 and P63 (pink) in the same individual.
22	Superficial (D), nodular (E) and infiltrative (F) sporadic BCCs from individuals without
23	BDCS stained for ARHGAP36 (green) and and P63 (pink). Scale bar $50\mu m$.


1 Fig. 5. ACTRT1 loss-of-function variants are unlikely to cause BDCS. Modelling of


- 2 maximum tolerated allele counts (MTAC) for the *ACTRT1* NM_138289.3:c.547dup
- 3 (p.(Met183Asnfs*17)) variant is shown. The left and right panels show MTACs against
- 4 different levels of possible prevalence and penetrance respectively. In both panels, the
- 5 blue lines model MTACs at the prevalence (left panel) or penetrance (right panel) levels
- 6 consistent with the existing literature. The green lines model MTACs at much lower
- 7 hypothetical constraints. Allele count estimates are for 204,684 alleles in the reference
- 8 population at 0.95 confidence interval, 33% allelic heterogeneity and genetic
- 9 heterogeneity of 1. Note that the observed population allele count (=373) of the variant,
- 10 shown in broken red line, is significantly higher than estimated maximum tolerated allele
- 11 counts across all the modelled scenarios.


12















F4




В Α F1:IV-3 ---- 2------.0. What with with site site out with with with with with with and F2:II-2 С F3:III-3 = 2:H1 2:H2 1:H2 2:H1 The second s _ ------L.O. . F7:II-1 .2 _ . 0. . . refseq ARHGAP36 IGSE1 -----ARHGAP36 IGSE1 F2 chrX:130,249,528-130,385,075 135,548bp chrX:130,385,075 CACCCAGTTCGAGCTTCCCGGCTTCT q26.1 q26.2 130,150,000 130,200,000 130,250,000 130.350.000 CACCCAGTTCGAGCTTCCCGGCTTCTGTGGGAGATAAGGGAGGATGGC 130,300,000 130,400,000 130,450,000 CTGTTGGGAGATAAGGGAG











F5:II-1 F8:II-4 F5:II-1 F5:I-1 F5:I-1 F3:III-1 F3:III-1 F3:III-3 F1:IV-3 F1:IV-4 F1:IV-4


chrX:130,249,526


130,242,	070	_	_			130,385,548
L1MA2	L1PA3	L1PB1	L1PA2L1P3	L1PA3	L1PA2	L1PA2
		F1.F3.F5	.F8			



Е







--- Observed population allele count